

Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis

Wei Kang^{1,2}, Joanna H.M. Tong^{1,2}, Anthony W.H. Chan¹, Tin-Lap Lee⁵, Raymond W.M. Lung^{1,2}, Patrick P.S. Leung^{1,2}, Ken K.Y. So^{1,2}, Kaichun Wu⁴, Daiming Fan⁴, Jun Yu^{2,3}, Joseph J.Y. Sung^{2,3}, and Ka-Fai To^{1,2}

Abstract

Purpose: Yes-associated protein 1 (YAP1) is a multifunctional protein that can interact with different transcription factors to activate gene expression. The role of YAP1 in tumorigenesis is unclear. We aimed to investigate the functional role of YAP1 in tumorigenesis of gastric cancer.

Experimental Design: YAP1 expression in gastric adenocarcinoma was evaluated. The biological function was determined by proliferation assay, colony formation, cell invasion, and flow cytometric analysis through knocking down or ectopic expressing YAP1 in gastric cancer cell lines coupled with *in vivo* study. The possible downstream effectors of YAP1 were investigated by expression microarray.

Results: YAP1 protein expression was upregulated in gastric cancer. Nuclear accumulation of YAP1 was associated with poor disease-specific survival ($P = 0.021$), especially in patients with early-stage diseases ($P < 0.001$). Knockdown YAP1 resulted in a significant reduction in proliferation, anchorage-dependent colony formation, cell invasion, and cell motility. Ectopic YAP1 expression promoted anchorage-independent colony formation, induced a more invasive phenotype, and accelerated cell growth both *in vitro* and *in vivo*. Microarray analysis highlighted the alteration of MAPK (mitogen-activated protein kinase) pathway by YAP1. We confirmed a constitutive activation of RAF/MEK/ERK (extracellular signal-regulated kinase) in YAP1-expressing MKN45 cells and further showed that YAP1 enhanced serum/epidermal growth factor-induced c-Fos expression in gastric cancer cells.

Conclusions: Our findings supported that YAP1 exhibits oncogenic property in gastric cancer. We provided the first evidence that YAP1 exerted the oncogenic function by enhancing the capacity to activate the early-response gene pathway. YAP1 could be a prognostic biomarker and potential therapeutic target for gastric cancer. *Clin Cancer Res*; 17(8); 2130–9. ©2011 AACR.

Introduction

Gastric cancer is one of the most common malignancies worldwide and is the second most frequent cause of cancer-

related death, with little improvement in long-term survival during the past decades. More than 700,000 people die from gastric cancer each year and more than 40% occur in China (1). Gastric cancer is thought to result from a combination of environmental and genetic factors. Various genetic, epigenetic, and molecular alterations are found in gastric cancer that underlies the multistep tumorigenic process. *Helicobacter pylori* infection, alterations in oncogenes, tumor suppressor genes, cell-cycle regulators, cell-adhesion molecules, and DNA repair genes, and genetic instability and telomerase activation are implicated in gastric tumorigenesis (2).

Yes-associated protein 1 (YAP1) is a 65-kDa proline-rich phosphoprotein located on chromosome 11q22.1. It is originally identified because of its interaction with the Src family tyrosine kinase Yes (3). It contains a WW domain, a PDZ interaction motif, an SH3 binding motif, and a coiled-coil domain (4). YAP1 has been found amplified in breast and liver cancers, where it promotes tumorigenesis (5, 6). Overexpression of YAP1 induces epithelial-to-mesenchymal transition, growth factor-independent proliferation, and suppression of apoptosis, suggesting a

Authors' Affiliations: ¹Department of Anatomical and Cellular Pathology, Sir Y. K. Pao Center for Cancer, State Key Laboratory in Oncology in South China; ²Institute of Digestive Disease and Li Ka Shing Institute of Health Sciences, and ³Department of Medicine, The Chinese University of Hong Kong, Hong Kong; ⁴State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China; and ⁵The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

W. Kang and J.H.M. Tong contributed equally to this work.

Corresponding Author: Ka-Fai To, Department of Anatomical and Cellular Pathology, Institute of Digestive Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong SAR, PR China. Phone: 852-26323334; Fax: 852-26376274. E-mail: kfto@cuhk.edu.hk

doi: 10.1158/1078-0432.CCR-10-2467

©2011 American Association for Cancer Research.

Translational Relevance

Gastric cancer remains a worldwide common malignancy with high mortality. Further understanding of gastric carcinogenesis is critical in searching for potential prognostic biomarkers and therapeutic targets. The function of Yes-associated protein 1 (YAP1) in gastric cancer is unclear. In this study, we showed that nuclear accumulation of YAP1 correlated with poor disease-specific survival. YAP1 was an independent prognostic marker, especially for patients with early-stage disease. The oncogenic property of YAP1 in gastric cancer was shown by *in vitro* and *in vivo* studies. We further investigated the downstream effectors of YAP1 by microarray analysis and confirmed experimentally. Our finding not only enhanced our understanding in the mechanisms of gastric carcinogenesis but also provided a potential diagnostic marker and therapeutic target for this aggressive malignancy.

role as an oncoprotein. Recent studies have established YAP1 as a transcription cofactor and a downstream effector of the MST2-WW45-Lats1/2 (Hpo-Sav-Wts in *Drosophila*) signaling, a pathway that controls cell growth and organ size (7, 8). In contrast, other studies identify that YAP1 can stabilize p73 posttranslationally and therefore activate the transcription of proapoptotic genes in response to apoptotic stimuli (9). Together with the evidence that upregulation of YAP1 correlates with better survival in a cohort of breast cancer patients (10), its activity is thought to favor tumor suppression. It has been proposed that whether YAP1 is anti- or protumorigenic is dependent on cell context and type of stimuli. Posttranslational modifications and binding affinity of protein-protein interaction domains are also critical in determining the biological role of YAP1 (9). Given that little is known about the function of YAP1 in gastric cancer, we aimed to examine its potential role in tumorigenesis of gastric cancer by both ectopic expression and knockdown approaches.

Materials and Methods

Cell lines

Nine human gastric cancer cell lines, MKN45, MKN28, KATO-III, AGS, NCI-N87, SNU1, SNU16, MKN1, and MKN7, were obtained from either the American Type Culture Collection or RIKEN Cell Bank.

Primary gastric adenocarcinoma specimens

A total of 30 primary gastric adenocarcinomas (GAC) and their paired noncancerous gastric mucosal tissues were obtained from the Endoscopy Centre of the Prince of Wales Hospital. Another 10 GACs and paired noncancerous gastric mucosal tissues from patients who underwent curative surgery were collected. All specimens were immediately snapped frozen in liquid nitrogen and stored at -80°C until pro-

cessing. A cohort of 129 formalin-fixed, paraffin-embedded tissues of GACs diagnosed between 1998 and 2002 in the Prince of Wales Hospital was retrieved. The clinicopathologic information was summarized in Supplementary Table S1A. In brief, the median age of the patients was 69 years (range: 38–88 years) and male to female ratio was 1.8:1. The median follow-up time was 17.2 months (range: 0.3–143.4 months). The study protocol was approved by the Joint CUHK (Chinese University of Hong Kong)-NTE Clinical Research Ethics Committee, Hong Kong, PR China.

Quantitative real-time PCR

Total RNA was prepared by TRIzol reagent (Invitrogen), and reverse transcription was done by using high-capacity cDNA reverse transcription kit (Applied Biosystems). Quantitative real-time PCR (qRT-PCR) was run on ABI 7500 real-time fast PCR system (Applied Biosystems) by using primers listed in Supplementary Table S2. All reactions were done in triplicate. The relative expression level was normalized with β -actin and calculated by the $2^{-\Delta\Delta\text{Ct}}$ method.

Immunohistochemistry

Immunohistochemistry was performed on the Ventana Nex ES automated Stainer (Ventana Corporation) by using anti-YAP1 antibody (1:100; Abcam). Antigen retrieval was performed by using pressure cooker with 10 nmol/L citrate buffer (pH 6.0) for 4 minutes. The nuclear expression of YAP1 was scored by estimating proportion of tumor cells with positive nuclear staining (0, none; 1, $\leq 10\%$; 2, 10% to $\geq 50\%$; 3, $> 50\%$). The cytoplasmic expression of YAP1 was assessed by assigning a proportion score and an intensity score. The proportion score was according to proportion of tumor cells with positive cytoplasmic staining (0, none; 1, $\leq 10\%$; 2, 10% to $\geq 25\%$; 3, > 25 to 50%; 4, $> 50\%$). The intensity score was assigned for the average intensity of positive tumor cells (0, none; 1, weak; 2, intermediate; 3, strong). The cytoplasmic score of YAP1 was the product of proportion and intensity scores, ranging from 0 to 12. The cytoplasmic expression was categorized into low (score 0–3), intermediate (score 4–6), and high (score 7–12). The scoring was independently assessed by 2 pathologists (K.F.T. and A.W.H.C.).

Western blot analysis

Western blot analysis was performed as previously described (11). The primary antibodies used were YAP1 (Abcam), extracellular signal regulated kinase (ERK)1/2, phosphorylated-ERK1/2 (p-ERK1/2), and c-Fos (all from Cell Signaling). All horseradish peroxidase-conjugated secondary antibodies used were purchased from DAKO.

Vector construction and transfection

Full-length YAP1 was amplified by PCR and cloned into pcDNA3.1(+), from Invitrogen, to produce YAP1 expression vector and transfected into MKN45 cells using Genejuice (Novagen). Stable YAP1-expressing clones

were selected using G418. Restoration of YAP1 expression was confirmed by Western blot analysis. HP Validated siRNAs targeting YAP1 were purchased from Qiagen (catalog no. S102662954) and transfected into AGS and MKN1 cells by using Lipofectamine 2000 (Invitrogen). Successful knockdown was confirmed by qRT-PCR and Western blot.

Cell proliferation and colony formation assays

Cell proliferation was assessed using CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT; Promega) according to the manufacturer's instructions. Monolayer colony formation assay and anchorage-independent soft agar assay were done as described previously (12).

Cell invasion

The invasive capacity of cells was determined using the BD BioCoat Matrigel invasion chambers (BD Biosciences). Transfection cells were seeded on the top chamber of each insert, with complete medium added to the bottom chamber. After 24 hours, cells on the membrane were wiped off with a cotton swab. After fixed and stained with 1% toluidine blue, cells on the underside of the membrane were counted from 5 microscope fields (original magnification \times 400). Each experiment was carried out in triplicate, and the mean value was expressed from 2 independent experiments.

Cell-cycle analysis

Cell-cycle analysis was done by flow cytometry as described previously (13).

Apoptosis assay

Early apoptosis was detected using Annexin V-FITC (fluorescein isothiocyanate) apoptosis detection kit (Bio-Vision) according to the manufacturer's instruction.

In vivo tumorigenicity

MKN45 cells (1×10^6 cells suspended in 0.1 mL PBS), transfected with YAP1 expression vector or empty vector, were injected subcutaneously into the dorsal flank of five 4-week-old male Balb/c nude mice (YAP1-expressing clones on the right and vector control clones on the left). Tumor diameter was measured and documented every 3 days until the end of week 3. Tumor volume (mm^3) was estimated by measuring the longest and shortest diameter of the tumor and calculating as follows: $\text{volume} = (\text{shortest diameter})^2 \times (\text{longest diameter}) \times 0.5$. The experiment was repeated for 3 times. The animal handling and all experimental procedures were approved by the Animal Ethics Committee of the CUHK.

Expression microarray

Human genome U133 Plus 2.0 GeneChip (Affymetrix) was applied to identify the transcript expression profiles. It provides comprehensive genome-wide expression analysis of more than 47,000 transcripts and variants. The raw data were quantile normalized by robust multiarray average

algorithm and analyzed in Partek Genomics Suite 6.4 (Partek). Differential gene expression was evaluated by 1-way ANOVA. A fold change cutoff of 1.5 and false discovery rates (FDR) less than 5% were set to identify differentially expressed gene between YAP1-expressing MKN45 cells and vector controls, or siYAP1-knockdown AGS cells and the scramble controls. The integrated gene network analysis on the gene set with significant expression changes was generated by Ingenuity Pathways Analysis (IPA; Ingenuity Systems, www.ingenuity.com). Each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base. These genes, called focus genes, were overlaid onto a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base. Networks of these focus genes were then algorithmically generated on the basis of their connectivity. Fischer's exact test was used to calculate a *P* value determining the probability that each biological function and/or disease assigned to that data set is due to chance alone. A *P* value of less than 0.01 was considered significant.

Statistical analysis

The Mann-Whitney *U* test was used to compare the difference in biological behavior between YAP1-expressing MKN45 cells and empty vector-transfected MKN45, or siYAP-knockdown AGS cells and scramble siRNA-transfected AGS cells. Correlations between YAP1 nuclear/cytoplasmic stain and clinicopathologic parameters were assessed by the nonparametric Spearman's rho rank test. The Kaplan-Meier method was used to estimate the survival rates for each variable. The equivalences of the survival curves were tested by log-rank statistics. For those variables being statistically significant found in the univariate survival analysis ($P < 0.05$), the Cox proportional hazards model with the likelihood ratio statistics was employed to further evaluate them for multivariate survival analysis. All statistical analyses were carried out by using statistical program SPSS version 16.0. A 2-tailed $P < 0.05$ value was regarded as statistically significant.

Results

Upregulation of YAP1 protein expression in gastric cancer

Overexpression of YAP1 mRNA was found in 6 of 9 gastric cell lines (Fig. 1A). The upregulation of YAP1 protein in these cell lines was confirmed by Western blot analysis (Fig. 1B). In primary GAC, 11 of 30 cases (36.7%) showed more than 1.5-fold upregulation of YAP1 mRNA expression in tumor tissues compared with paired non-cancerous gastric mucosal tissues. However, the mean level of YAP1 mRNA expression in 30 tumor tissues was not significantly higher than that in the normal tissues [3.1 (0.19–16.43) vs. 2.5 (0.16–8.46), $P = 0.134$; Fig. 1C]. By Western blotting, YAP1 protein was found upregulated in 9 of 10 gastric cancers compared with their noncancerous counterparts (Fig. 1D).




Figure 1. Overexpression of YAP1 in GAC. **A**, YAP1 mRNA level was measured by qRT-PCR in gastric cancer cell lines. The experiment was done in triplicate. The error bars represent the SDs. The normal tissue corresponds to human stomach total RNA commercially available from Ambion (AM7996). **B**, YAP1 protein level was determined by Western blot analysis in gastric cancer cell lines and normal gastric mucosa. (Normal 1 and 2 samples were the normal gastric mucosa obtained from weight reduction gastric surgery.) **C**, the box plot shows the YAP1 mRNA expression level from 30 cases of GAC and paired noncancerous gastric mucosa; no significance ($P = 0.134$). **D**, expression of YAP1 protein in paired gastric cancer (T) and noncancerous gastric mucosa (N) was determined by Western blot analysis. **E**, immunohistochemical analysis of YAP1 expression in GAC. Case 49, an example of intestinal type GAC. Case 102, an example of diffuse type GAC (original magnification $\times 100$; insert, original magnification $\times 400$).

Immunohistochemistry was performed to assess the YAP1 protein expression in tissue microarrays containing 129 formalin-fixed, paraffin-embedded GACs. Gastric carcinoma cells often exhibited cytoplasmic and nuclear expression of YAP1 (Fig. 1E). Since the subcellular localization is critical in determining the functions of YAP1, both the cytoplasmic staining and the nuclear staining were scored separately. Marked nuclear immunoreactivity was seen in 42% (54/129) of the GACs. Intermediate and low nuclear staining was noted in 31% (40/129) and 19% (25/129), respectively. Ten GAC samples (8%) showed negative nuclear staining of YAP1. For the cytoplasmic localization of YAP1, strong and moderate immunoreactivity was seen in 32% (41/129) and 42% (54/129) of GACs, respectively. Weak and negative YAP1 cytoplasmic immunoreactivity accounted for 26% (34/129) of the tumor samples.

Association of YAP1 expression with clinicopathologic characteristics

Upregulation of YAP1 nuclear expression in gastric cancer was associated with a poorer disease-specific survival by univariate analysis ($P = 0.021$; Fig. 2A). Univariate analysis indicated that other factors including female gender ($P = 0.027$), histology with diffuse component ($P = 0.021$), higher tumor grade ($P = 0.037$), and advance stage ($P < 0.001$) also correlated with poor survival (Supplementary Table S1A). By multivariate Cox proportional hazards regression analysis, only stage was independently associated with disease-specific survival ($P < 0.0001$). However, in patients with early-stage diseases (stages I and II), a

strong association for higher nuclear YAP1 expression (score 2 or higher) with shorter disease-specific survival ($P < 0.001$; Fig. 2B) was shown. To examine the clinical significance of YAP1 as a predictive marker for disease-specific survival in early-stage gastric cancer, we recruited another 65 cases of stage I and II gastric cancers for further analysis. In a cohort of 101 early-stage gastric cancers, the YAP1 low-expression subgroup (score 0 or 1; $n = 23$) had a significantly better prognosis than YAP1 high-expression subgroup (score 2 or 3; $n = 78$) by Kaplan–Meier analysis ($P = 0.040$; Supplementary Fig. S1). Multivariate Cox regression showed that YAP1 was an independent predictor of disease-specific survival for patients in early-stage disease ($P = 0.042$) in addition to T stage disease ($P = 0.038$). Nuclear expression of YAP1 did not associate with age, gender, histologic type, grading, staging, or the presence of *H. pylori* (Supplementary Table S1B and C). Cytoplasmic expression of YAP1 did not associate with survival or other clinicopathologic parameters.

YAP1 knockdown in gastric cancer cells

On siRNA-mediated suppression, a significantly decreased proliferation was observed in gastric cancer cell lines MKN1 and AGS compared with scramble siRNA and mock control groups ($P < 0.001$; Fig. 3A). Monolayer colony formation assay indicated that YAP1 knockdown significantly reduced colony formation in these cell lines ($P < 0.001$; Fig. 3B). In cell invasion assay, a significant reduction in the invasive phenotype through the Matrigel-coated Boyden chamber was noted on YAP1 knockdown




Figure 2. Kaplan-Meier plots of disease-free survival according to YAP1 nuclear expression status. A, YAP1 nuclear accumulation associated with poor disease-specific survival in patients with GAC. B, YAP1 nuclear accumulation (score 2 or higher) also significantly predicted poor survival in patients with early-stage diseases (stage I/II).

($P < 0.001$; Fig. 3C). Since a growth inhibitory effect was observed in siYAP1-transfected cells, we analyzed the transfectants for cell-cycle parameters by flow cytometry. Twenty-four hours after transfection, accumulation of G_1 cells increased in siYAP1 transfectant compared with the scramble siRNA controls (Fig. 3D; 72% vs. 55% in MKN1 and 49% vs. 37% in AGS cells). Cell apoptosis, as determined by sub- G_1 phase, increased from 0.56% to 17% in AGS cells. However, siYAP1 did not change the percentage of sub- G_1 cells in MKN1 (Fig. 3E). Similar finding was observed by Annexin V assay (data not shown). Thus, the apoptotic response seemed to be cell context-dependent. MKN1 cells harbor the TP53 mutation at the DNA-binding (core) domain (V143A), whereas AGS cells carry the wild-type TP53 (Supplementary Fig. S2). It is uncertain whether the different TP53 status might contribute to the different apoptotic response to YAP1 knockdown between the 2 cell lines. Taken together, siRNA knockdown of YAP1 in MKN1 and AGS cells resulted in a significant reduction in proliferation, anchorage-dependent colony formation, and cell invasion. G_1 arrest was observed in both cell lines upon YAP1 knockdown, yet the apoptotic response seemed to be cell context-dependent.

YAP1 overexpression in MKN45

The expression of YAP1 was completely lost in gastric cancer cell line MKN45 because of an intragenic homozygous deletion (Supplementary Fig. S3). It therefore provided an *in vitro* model to study the YAP1 ectopic expression. We transfected pcDNA3.1(+)/YAP1 or empty vector into MKN45 cells and the clones that stably expressing YAP1 were selected by G418. Reexpression of YAP1 was confirmed by immunohistochemistry and Western blot (Fig. A and E). Transfection of YAP1 into MKN45 cells

increased cell proliferation in both high and low serum conditions (Fig. 4A). A significant increase in the number of invading cells through the Matrigel-coated membrane in pcDNA3.1(+)/YAP1-transfected group was shown when compared with the vector-alone group ($P < 0.001$; Fig. 4B). We further examined the effect of YAP1 on the ability to form colonies in soft agar, a more stringent parameter of oncogenic property. YAP1-expressing MKN45 cells formed larger colonies in soft agar by 14 days, and the number of colonies was significantly increased by 44 folds ($P < 0.001$) compared with the vector controls (Fig. 4C), suggesting that YAP1 promoted anchorage-independent growth. The effect of YAP1 expression on *in vivo* growth of tumor was studied by subcutaneous injection of YAP1-expressing MKN45 clones into nude mice. The tumor growth in YAP1-expressing clones was significantly enhanced compared with the vector control clones ($P < 0.001$; Fig. 4D). In summary, overexpression of YAP1 accelerated cell growth both *in vitro* and *in vivo*, promoted anchorage-independent colony formation, and induced a more invasive phenotype in MKN45 cells.

Identification of cellular networks and pathways regulated by YAP1

To gain insight into the mechanisms by which YAP1 exerts the oncogenic function, we compared gene expression profiles of YAP1-expressing MKN45 cells (YAP1-MKN45) versus vector controls (vector-MKN45) and YAP1-knockdown AGS cells (siYAP1-AGS) versus scramble controls (scramble-AGS). Differential gene expression was evaluated by 1-way ANOVA. Genes that had greater than 1.5-fold differences in expression levels over the controls with FDRs less than 5% were selected for the IPA. Selected up- and downregulated genes were validated by qRT-PCR




Figure 3. Knockdown of YAP1 by RNA interference in gastric cancer cell lines MKN1 and AGS. **A**, MTT assay suggested that knockdown YAP1 by siRNA significantly suppressed proliferation in MKN1 and AGS cells. The mean and SD obtained from 7 experiments are plotted (**, $P < 0.001$). **B**, monolayer colony formation assay showed that YAP1 knockdown reduced anchorage-dependent colony formation (**, $P < 0.001$). The experiment was done in triplicate, and the error bars represent SDs. **C**, a significant reduction in the invasive ability was shown on YAP1 knockdown compared with scramble siRNA-treated cells. Representative images of cells invaded through the Matrigel-coated membrane to the underside of micropores are shown (**, $P < 0.001$). **D**, flow cytometric analysis suggested the accumulation of cells in G₁ phase in 24 hours after siYAP1 treatment. Representative data from 3 independent experiments are shown. **E**, knockdown YAP1 increased sub-G₁ population in AGS but not in MKN1 cells, suggesting that inhibition of apoptosis by YAP1 was cell context-dependent. The representative data from 3 independent experiments are shown.

(Supplementary Table S3). A total of 27 partially overlapped networks with IPA score greater than 11 were linked to YAP1 regulation. All networks involved more than 11 focus genes. Top functions of these genes were related to cancer, cell cycle, digestive system development and function, small molecule biochemistry, and lipid metabolism. The 10 networks with the highest rank are shown in Supplement Table S4.

Induction of proto-oncogene *c-Fos* by YAP1

Close examination of the networks identified that mitogen-activated protein kinases (MAPK) family genes were enriched in several networks. For example, the network associated with "cancer, cellular movement, and neurologic disease," incorporating 23 focus genes, was centered on ERK (Supplementary Fig. S4A). Another network built on 22 focus genes was mostly centered on MAPK and associated with lipid metabolism, molecular transport, and

small molecule biochemistry (Supplementary Fig. S4B). MAPK pathway is involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation, and development. The pathway is also a key target of cell transformation in tumor development. We compared the expression of MAPK family genes in YAP1-MKN45 cells with vector-MKN45. Activation of MAPK pathway by YAP1, as indicated by elevated phosphorylated c-Raf/MEK1/2/ERK1/2 and c-Fos, was observed in MKN45 cells stably expressing YAP1 (Fig. 4E).

To further address the effect of YAP1 expression on the activation of MAPK signaling, we stimulated YAP1-MKN45 and vector-MKN45 cells with serum after starvation for 24 hours. Western blot analysis was then done to assess the level of p-ERK1/2 and c-Fos (Fig. 5A). Stronger ERK1/2 activation at 1 minute post-serum stimulation was observed in YAP1-expressing cells compared with the vector-transfected cells. c-Fos was induced by serum at 30




Figure 4. Ectopic expression of YAP1 in MKN45 cells. **A**, reexpression of YAP1 in MKN45 cells after transfection was confirmed by immunohistochemistry. Ectopic expression of YAP1 increased proliferation in both high and low serum conditions (*, $P < 0.05$; **, $P < 0.001$). The mean and SD obtained from 3 experiments are plotted. **B**, a significant increase of invasion ability of MKN45 cells through the Matrigel-coated membrane was observed in YAP1-transfected cells compared with vector controls (**, $P < 0.001$). The experiment was done in triplicate and the error bars represent SDs. **C**, YAP1-expressing cells formed larger colonies in soft agar by 14 days, and the number of colonies was significantly increased compared with the vector controls (**, $P < 0.001$). The experiment was done in triplicate, and the error bars represent SDs. **D**, YAP1-expressing MKN45 cells and vector-transfected controls were injected subcutaneously to the right and left dorsal flank of nude mice, respectively. Three weeks after injection, the tumor size of YAP1-MKN45 was significantly larger than vector-MKN45 (**, $P < 0.001$). The mean and SD obtained from 5 mice are plotted. Representative results from 3 independent experiments are shown. The YAP1 expression in xenograft tumors was confirmed by immunohistochemistry. **E**, Western blot analysis showed upregulation of MAPK pathway in MKN45 cells stably expressing YAP1.

minutes and was maximal at 60 minutes. Ectopic expression of YAP1 resulted in a much stronger c-Fos induction in gastric cancer cells. The MEK inhibitor PD98095 inhibited ERK activation and c-Fos induction (Fig. 5C), indicating that YAP1 regulated the serum-induced c-Fos induction through MAPK pathway. The enhanced capacity on c-Fos induction was also observed when stimulated the cells with epidermal growth factor (EGF; Fig. 5B). *c-Fos* is an immediate early gene whose expression is a key switch in cellular regulation. Together with *c-Jun*, it forms the AP-1 complex required for the transcription of many genes important for cell growth, differentiation, and transformation. Our data suggested that c-Fos is a target for the function of YAP1. The early gene responses are representative of the events that initiate progression through the cell cycle. YAP1 might exert

its growth-promoting effect, at least in part, by upregulating c-Fos in gastric cancer cells.

Discussion

In this study, we observed an overexpression of YAP1 in gastric cancers. This result was in keeping with a previous report that overexpression of YAP1 was found in 48% of the gastric cancer (14). Upregulation of YAP1 was also found in colon cancer, lung adenocarcinoma, ovarian cancer, hepatocellular carcinoma, and prostate cancer (8, 15, 16). The findings suggested a potential oncogenic role of YAP1 in multiple human cancers. More important, we have shown that YAP1 nuclear accumulation significantly was associated with poorer disease-specific survival, particularly




Figure 5. YAP1 enhanced serum/EGF-stimulated c-Fos induction. A and B, YAP1-MKN45 (+) and vector-MKN45 cells (-) were cultured without serum for 24 hours and then stimulated with serum or EGF for 0, 1, 5, 15, 30, 60, and 90 minutes. Cells were immediately washed with cold PBS and collected by scraping. The cell lysates were analyzed for the MAPK pathway by Western blot analysis by using antibodies against p-ERK1/2 and c-Fos. Representative of 3 independent experiments is shown. C, YAP1-MKN45 and vector MKN45 cells were seeded onto 35-mm plates and cultured without serum for 24 hours. By the end of the 24-hour incubation, the MEK inhibitor PD98059 (20 μ M; Calbiochem) was added to 1 set of cells for 2 hours. The cells were then stimulated with 10% serum for 0, 5, 15, 30, 60, and 90 minutes. The cell lysates were analyzed for MAPK activation and c-Fos expression by Western blot analysis. Treatment with PD98059 suppressed ERK1/2 phosphorylation and c-Fos induction in MKN45 cells.

in patients with early-stage GAC. Our data provided the first evidence that YAP1 could be used as a potential prognostic biomarker, especially for patients with early-stage disease.

YAP1 functions as a transcription coactivator to regulate gene expression in nucleus (17–22). The Lats tumor suppressor kinase phosphorylates YAP1 at S127 and enhances its interaction with 14-3-3 proteins, resulting in YAP1 cytoplasmic sequestration and thereby rendering it unable to function as a transcription coactivator (7). Therefore, it is believed that the subcellular localization is important in determining the biological significance of YAP1. Although we observed an overall upregulation of cytoplasmic YAP1 expression in gastric cancer cells, the cytoplasmic expression of YAP1 did not

correlate with any of the clinicopathologic parameters. Our finding reiterated the functional significance of YAP1 nuclear localization.

Chromosome 11q22, where YAP1 is located, is a recurrent amplicon in hepatocellular carcinoma and esophageal squamous cell carcinoma (6, 23). Amplification of this region, although infrequent, has been implicated in various human cancers (24–29). Our array CGH (comparative genomic hybridization) analysis revealed amplification of YAP1 in 1 of 9 gastric cancer cell lines only (NCI-N87; Supplementary Fig. S3). Consistently high YAP1 mRNA and protein levels were detected in this cell line. However, overexpression of YAP1 was also seen in cell lines without gene amplification such as MKN28 and AGS). Mechanisms other than gene amplification must contribute to the YAP1 overabundance in gastric cancer cells (e.g., transcription, activation, or protein stabilization). Upregulation of YAP1 mRNA expression was observed in a subset (36.7%) of GAC. But the mean level of YAP1 expressions in tumor tissues was not significantly higher than that in paired noncancerous gastric tissues (Fig. 1C). By immunohistochemistry, YAP1 protein expression was found in most GACs whereas only scanty cells were positive in normal gastric mucosa. In addition, no YAP1 mutation was detected in 8 gastric cancer cell lines and 10 primary gastric tumors (Supplementary Methods). We speculated that a major mechanism for YAP1 accumulation in gastric cancer cells might be related to posttranslational modification or interaction with other cellular proteins that stabilize YAP1, which is a negatively regulated downstream target of the Hippo signaling pathway. The mammalian Hippo orthologues MST1/MST2 protein kinases suppress the oncogenic activity of YAP1 by promoting YAP1 S127 phosphorylation and subsequent cytoplasmic retention. Dysregulation of the Hippo pathway has been implicated in tumorigenesis (7, 8). We have shown the loss of cleaved activated MST1/2 in gastric cancer tissues (Supplementary Methods and Supplementary Fig. S5A), suggesting that the MST-YAP1 pathway is disrupted in a substantial fraction of gastric cancers. The finding was in keeping with previous studies that downregulation of MST1/2 was observed in sarcomas and various cancers (30, 31). In addition, *in vitro* studies showed that ectopic expression of MST1 suppressed cell proliferation and induced apoptosis in gastric cancer cells (Supplementary Fig. S5B). We have further shown that MST1 promoted the phosphorylation of YAP1 on S127, enhanced its retention in the cytoplasm, and therefore quenched its oncogenic function in the nucleus (Supplementary Fig. S5C). The data indicated that activation of YAP1 in gastric cancer might be related to disruption of the Hippo pathway.

There is no DNA-binding domain on YAP1 protein. It interacts with several transcription factors, including RUNX2, SMAD7, p73, p53BP2, and TEAD family members, and modulates their transcriptional activity. The TEAD proteins are major partners of YAP1 and are required for the YAP1-mediated gene expression that promotes proliferation and inhibits apoptosis (22). On

the other hand, YAP1 physically interacts with p73 α , p73 β , and p63 α and promotes apoptosis following DNA damage (32). The precise biological function of YAP1 is not clear. The choice of its partner transcription factors and, consequently, the final outcome might be determined by multiple factors such as cell context, type of stimuli, and regulation of upstream pathways. We showed in this study the upregulation of YAP1 in gastric cancers. The accumulation of YAP1 in tumor cells suggests that it might be a candidate oncoprotein. Functional studies also supported a tumorigenic role of YAP1 in gastric cancer. Knockdown YAP1 in gastric cancer cell lines led to a dramatic decrease in proliferation and colony formation, whereas ectopic YAP1 expression significantly increased cell growth both *in vitro* and *in vivo*. This is in keeping with previous studies, which implicate YAP1 as an oncogene (5, 6). Being an adaptor protein with the capacity to interact with multiple transcription factors, YAP1 is placed at the crossroads of multiple

signaling pathways. It has been proposed that YAP1 regulates the balance between cell proliferation and apoptosis to maintain homeostasis (8). Further investigation therefore has to be done to clarify the role it plays in physiologic condition and during tumorigenesis.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

The project was supported by a research grant of National Basic Research Program of China (973 Program, 2010CB529305).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 20, 2010; revised November 9, 2010; accepted December 9, 2010; published OnlineFirst February 23, 2011.

References

- Leung WK, Chan MC, To KF, Man EP, Ng EK, Chu ES, et al. *H. pylori* genotypes and cytokine gene polymorphisms influence the development of gastric intestinal metaplasia in a Chinese population. *Am J Gastroenterol* 2006;101:714–20.
- Milne AN, Carneiro F, O'Morain C, Offerhaus GJ. Nature meets nurture: molecular genetics of gastric cancer. *Hum Genet* 2009;126:615–28.
- Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. *Oncogene* 1994;9:2145–52.
- Bork P, Sudol M. The WW domain: a signalling site in dystrophin? *Trends Biochem Sci* 1994;19:531–3.
- Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. *Proc Natl Acad Sci U S A* 2006;103:12405–10.
- Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. *Cell* 2006;125:1253–67.
- Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. *Cancer Cell* 2008;13:188–92.
- Zhao B, Wei X, Li W, Udani RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev* 2007;21:2747–61.
- Strano S, Blandino G. YAP1 meets tumor suppression. *Mol Cell* 2007;27:863–4.
- Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. *Cell Death Differ* 2008;15:1752–9.
- Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL, et al. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. *Neoplasia* 2009;11:1174–84.
- Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. *Gastroenterology* 2009;136:640–51.e1.
- Li J, Ng EK, Ng YP, Wong CY, Yu J, Jin H, et al. Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer. *Br J Cancer*. 2009;101:691–8.
- Da CL, Xin Y, Zhao J, Luo XD. Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. *World J Gastroenterol*. 2009;15:4055–61.
- Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. *Cancer* 2009;115:4576–85.
- Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, et al. Expression of Yes-associated protein in common solid tumors. *Hum Pathol* 2008;39:1582–9.
- Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. *EMBO J* 2004;23:790–9.
- Ferrigno O, Lallemand F, Verrecchia F, L'Hoste S, Camonis J, Atfi A, et al. Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling. *Oncogene* 2002;21:4879–84.
- Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. *J Biol Chem* 2003;278:33334–41.
- Levy D, Adamovich Y, Reuven N, Shaul Y. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. *Cell Death Differ* 2007;14:743–51.
- Espanel X, Sudol M. Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. *J Biol Chem* 2001;276:14514–23.
- Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. *Genes Dev* 2008;22:1962–71.
- Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, Imamura M, et al. Identification of clAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. *Cancer Res* 2001;61:6629–34.
- Lee JJ, Au AY, Foukakis T, Barbaro M, Kiss N, Clifton-Bligh R, et al. Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. *Endocr Relat Cancer* 2008;15:801–15.
- Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. *Neuro Oncol* 2009;11:477–87.
- Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, et al. Expression of clAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. *Cancer Res* 2002;62:4860–6.
- Dai Z, Zhu WG, Morrison CD, Brena RM, Smiraglia DJ, Raval A, et al. A comprehensive search for DNA amplification in lung cancer identifies

- inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. *Hum Mol Genet* 2003;12:791–801.
28. Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, Karikari CA, et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. *Neoplasia* 2005;7:556–62.
29. Vauhkonen H, Vauhkonen M, Sipponen P, Knuutila S. Oligonucleotide array comparative genomic hybridization refines the structure of 8p23.1, 17q12 and 20q13.2 amplifications in gastric carcinomas. *Cytogenet Genome Res* 2007;119:39–45.
30. Kosaka Y, Mimori K, Tanaka F, Inoue H, Watanabe M, Mori M. Clinical significance of the loss of MATS1 mRNA expression in colorectal cancer. *Int J Oncol* 2007;31:333–8.
31. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. *Mol Carcinog* 2007;46:865–71.
32. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. *Mol Cell* 2005;18:447–59.

Clinical Cancer Research

Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis

Wei Kang, Joanna H.M. Tong, Anthony W.H. Chan, et al.

Clin Cancer Res 2011;17:2130-2139. Published OnlineFirst February 23, 2011.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-10-2467](https://doi.org/10.1158/1078-0432.CCR-10-2467)

Supplementary Material Access the most recent supplemental material at:
<http://clincancerres.aacrjournals.org/content/suppl/2011/04/14/1078-0432.CCR-10-2467.DC1>

Cited articles This article cites 32 articles, 8 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/17/8/2130.full#ref-list-1>

Citing articles This article has been cited by 13 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/17/8/2130.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/17/8/2130>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.